Emerging Trends

UGenome Media & In the News

See more about UGenome from sources across the genomic medicine world.

UGenome Partners with Jura Health to Speed up and Improve Rare Disease Diagnosis & Treatment

TUCSON A.Z. – UGenome AI, a pioneer in genomic platforms to fuel personalized medicine, today announced a strategic partnership with Jura Health, Inc. to leverage UGenome technology for rare disease patient diagnosis and personalized plans. This collaboration will empower those with rare genetic disorders to learn about their pharmacogenomic profile faster, shorten diagnosis and treatment timelines, and support disease outcomes.

UGenome Co-Founder Highlighted in Valar Institute

Meet Valar Executive MBA alumnus, Jayden Lee — a clinical pharmacist turned biotech innovator on a mission to transform healthcare. Jayden is the co-founder of UGenome AI, a genomics software startup poised to revolutionize disease prevention, management, and treatment. Learn about Jayden’s journey and how Valar empowered him to #takethelead.

UGenome named #2 Biotech Startup in the State of Arizona February 2025

We’re tracking  AniCell Team, UGenome AI and more Biotech companies in Arizona from the F6S community. Biotech is the 33rd most popular industry and market group. If you’re interested in the Biotech market, also check out the top Green Biotechnology, Red Biotechnology, Biodegradable Plastics, Fermentation or Blue Biotechnology companies.

Pharmacogenomics Offers New Frontier For Precision Medicine | MedCity News - UGenome Thought Leadership

Imagine a set of twins who have a family history of migraines. They both go to the pharmacy and pick up the migraine medication prescribed by the doctor. The prescription works for one twin, but the second still has a migraine. A variety of factors drive such a phenomenon: how quickly the person metabolizes the drug, if the twin has a sensitivity to that medication, and other factors.

Biotech & Lifescience CEO Podcast | Zachary S. Brooks, PhD - UGenome Founder & CEO

Feb 12, 2025. It’s shocking that 106,000 people die every year from adverse drug reactions. Moreover, 350,000 people are hospitalized every year, 1.3 million people go to the ER, and it is the fourth leading cause of death in the United States. Adverse drug reactions are a behemouth problem, costing the economy almost half trillion dollars. Zach Brooks is the founder and CEO of UGenome AI, whose mission is to democratize access to genomic information in the pursuit of personal medicene. His company is hoping to replace “trial and error” with more reliable outcomes and fewer unintended consequences. Disclaimer

Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine | MedCity News - UGenome Thought Leadership

Pharmacogenomics (PGx), the study of how genetic profiles impact an individual’s responses to medication, has already begun to help healthcare providers (HCPs) optimize care through its capacity to preemptively enhance drug efficacy, minimize adverse side effects, and improve patient experiences. This rapidly growing field marries bioinformatics and pharmacology and represents a transformative new era of precision medicine and highly personalized treatments, one that serves patients by supporting clinicians to better predict therapeutic responses and more accurately optimize drug dosages.

We promise we don’t send spam